|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
|
MX2011009796A
(es)
|
2009-03-20 |
2011-12-14 |
Amgen Inc |
Inhibidores de la cinasa pi3.
|
|
PH12012500778A1
(en)
|
2009-10-30 |
2012-11-26 |
Janssen Pharmaceutica Nv |
IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
|
|
EP2526102B1
(en)
*
|
2010-01-22 |
2017-03-08 |
Fundación Centro Nacional de Investigaciones Oncológicas Carlos III |
Inhibitors of PI3 kinase
|
|
AR080754A1
(es)
|
2010-03-09 |
2012-05-09 |
Janssen Pharmaceutica Nv |
Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
|
|
TW201200518A
(en)
*
|
2010-03-10 |
2012-01-01 |
Kalypsys Inc |
Heterocyclic inhibitors of histamine receptors for the treatment of disease
|
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
|
MX353408B
(es)
|
2010-04-22 |
2018-01-11 |
Vertex Pharma |
Proceso para producir compuestos de cicloalquilcarboxamido-indol.
|
|
US20130131057A1
(en)
|
2010-05-13 |
2013-05-23 |
Centro Nacional De Investigaciones Oncologicas (Cnio |
New bicyclic compounds as pi3-k and mtor inhibitors
|
|
EP2444084A1
(en)
|
2010-10-21 |
2012-04-25 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Use of PI3K inibitors for the treatment of obesity
|
|
WO2012052745A1
(en)
|
2010-10-21 |
2012-04-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Combinations of pi3k inhibitors with a second anti -tumor agent
|
|
TWI617559B
(zh)
|
2010-12-22 |
2018-03-11 |
江蘇恆瑞醫藥股份有限公司 |
２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
|
|
EP2524918A1
(en)
|
2011-05-19 |
2012-11-21 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Imidazopyrazines derivates as kinase inhibitors
|
|
BR112013033375B1
(pt)
|
2011-06-27 |
2022-05-10 |
Janssen Pharmaceutica N.V |
Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
|
|
DK2841075T3
(da)
|
2012-04-26 |
2020-06-22 |
Massachusetts Gen Hospital |
Midler og fremgangsmåder til behandling og forebyggelse af seboroisk keratose
|
|
CN103450204B
(zh)
*
|
2012-05-31 |
2016-08-17 |
中国科学院上海药物研究所 |
吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
|
|
CN102675323B
(zh)
*
|
2012-06-01 |
2014-04-09 |
南京药石药物研发有限公司 |
吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途
|
|
HK1206250A1
(en)
|
2012-06-26 |
2016-01-08 |
Janssen Pharmaceutica Nv |
Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders
|
|
WO2014009305A1
(en)
|
2012-07-09 |
2014-01-16 |
Janssen Pharmaceutica Nv |
Inhibitors of phosphodiesterase 10 enzyme
|
|
US9145411B2
(en)
|
2012-08-02 |
2015-09-29 |
Asana Biosciences, Llc |
Substituted amino-pyrimidine derivatives
|
|
WO2014186663A2
(en)
*
|
2013-05-17 |
2014-11-20 |
The General Hospital Corporation |
Methods for detecting and treating variants of seborrheic keratoses
|
|
MX373103B
(es)
|
2014-02-13 |
2020-04-17 |
Incyte Holdings Corp |
Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
|
|
US9527835B2
(en)
|
2014-02-13 |
2016-12-27 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
EP3105219B9
(en)
|
2014-02-13 |
2018-10-03 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
SI3105218T1
(sl)
|
2014-02-13 |
2019-11-29 |
Incyte Corp |
Ciklopropilamini kot inhibitorji LSD1
|
|
RU2744460C2
(ru)
|
2014-04-15 |
2021-03-09 |
Вертекс Фармасьютикалз Инкорпорейтед |
Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
|
|
WO2016007722A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
TW201613925A
(en)
|
2014-07-10 |
2016-04-16 |
Incyte Corp |
Imidazopyrazines as LSD1 inhibitors
|
|
TWI687419B
(zh)
|
2014-07-10 |
2020-03-11 |
美商英塞特公司 |
作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
|
|
WO2016007727A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
PL236355B1
(pl)
*
|
2015-04-02 |
2021-01-11 |
Celon Pharma Spolka Akcyjna |
Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
|
|
EP3277689B1
(en)
|
2015-04-03 |
2019-09-04 |
Incyte Corporation |
Heterocyclic compounds as lsd1 inhibitors
|
|
LT3334709T
(lt)
|
2015-08-12 |
2025-03-10 |
Incyte Holdings Corporation |
Lsd1 inhibitoriaus druskos
|
|
EP3365340B1
(en)
|
2015-10-19 |
2022-08-10 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
US20170145025A1
(en)
|
2015-11-19 |
2017-05-25 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
ES2916874T3
(es)
|
2015-12-17 |
2022-07-06 |
Incyte Corp |
Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
|
|
AU2016379372A1
(en)
|
2015-12-22 |
2018-08-02 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
CN105622526A
(zh)
*
|
2016-02-24 |
2016-06-01 |
湖北工业大学 |
一种2-氨基吡嗪衍生物的制备方法
|
|
SG11201808907PA
(en)
*
|
2016-04-15 |
2018-11-29 |
Blueprint Medicines Corp |
Inhibitors of activin receptor-like kinase
|
|
JP6999574B2
(ja)
|
2016-04-22 |
2022-01-18 |
インサイト・コーポレイション |
Ｌｓｄ１阻害剤の製剤
|
|
ES2906460T3
(es)
|
2016-05-06 |
2022-04-18 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
ES2905980T3
(es)
|
2016-05-26 |
2022-04-12 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
BR112018076534A2
(pt)
|
2016-06-20 |
2019-04-02 |
Incyte Corporation |
compostos heterocíclicos como imunomoduladores
|
|
MA45669A
(fr)
|
2016-07-14 |
2019-05-22 |
Incyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
|
ES2941716T3
(es)
|
2016-08-29 |
2023-05-25 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
TW202233190A
(zh)
*
|
2016-12-07 |
2022-09-01 |
英屬開曼群島商百濟神州有限公司 |
作為ＰＩ３Ｋδ抑制劑的咪唑並［１，５－Ａ］吡衍生物
|
|
ES2856248T3
(es)
*
|
2016-12-21 |
2021-09-27 |
Acerta Pharma Bv |
Inhibidores de imidazopirazina de la tirosina quinasa de Bruton
|
|
WO2018119286A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
|
ES2899402T3
(es)
|
2016-12-22 |
2022-03-11 |
Incyte Corp |
Derivados de piridina como inmunomoduladores
|
|
ES2874756T3
(es)
|
2016-12-22 |
2021-11-05 |
Incyte Corp |
Derivados de triazolo[1,5-A]piridina como inmunomoduladores
|
|
AU2017382870B2
(en)
|
2016-12-22 |
2022-03-24 |
Incyte Corporation |
Benzooxazole derivatives as immunomodulators
|
|
EP3558990B1
(en)
|
2016-12-22 |
2022-08-10 |
Incyte Corporation |
Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
|
|
WO2019048036A1
(en)
|
2017-09-06 |
2019-03-14 |
Biontech Ag |
SUBSTITUTED IMIDAZOQUINOLINES
|
|
TWI817956B
(zh)
|
2017-09-08 |
2023-10-11 |
英屬開曼群島商百濟神州有限公司 |
咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑
|
|
KR20240152947A
(ko)
|
2017-10-18 |
2024-10-22 |
인사이트 코포레이션 |
Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
|
|
BR112020018094A2
(pt)
|
2018-03-08 |
2020-12-22 |
Incyte Corporation |
Compostos de aminopirazina diol como inibidores de pi3k-¿
|
|
CR20200520A
(es)
|
2018-03-30 |
2021-03-09 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
WO2019217821A1
(en)
|
2018-05-11 |
2019-11-14 |
Incyte Corporation |
Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
|
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|
|
CR20250050A
(es)
|
2018-09-05 |
2025-03-19 |
Incyte Corp |
Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
|
|
WO2020052772A1
(en)
|
2018-09-13 |
2020-03-19 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Modulation of trf1 for brain cancer treatment
|
|
EP3623009A1
(en)
|
2018-09-13 |
2020-03-18 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Modulation of trf1 for brain cancer treatment
|
|
EP3623370A1
(en)
|
2018-09-13 |
2020-03-18 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Novel trf1 modulators and analogues thereof
|
|
EP4010342A1
(en)
|
2019-08-09 |
2022-06-15 |
Incyte Corporation |
Salts of a pd-1/pd-l1 inhibitor
|
|
WO2021067217A1
(en)
|
2019-09-30 |
2021-04-08 |
Incyte Corporation |
Pyrido[3,2-d]pyrimidine compounds as immunomodulators
|
|
BR112022009031A2
(pt)
|
2019-11-11 |
2022-10-11 |
Incyte Corp |
Sais e formas cristalinas de um inibidor de pd-1/pd-l1
|
|
US11718622B2
(en)
|
2020-03-16 |
2023-08-08 |
Exelixis Inc. |
Heterocyclic adenosine receptor antagonists
|
|
IL301244A
(en)
|
2020-09-28 |
2023-05-01 |
1St Biotherapeutics Inc |
INDOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS OF USING THEM
|
|
WO2022099075A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Crystalline form of a pd-1/pd-l1 inhibitor
|
|
US11866434B2
(en)
|
2020-11-06 |
2024-01-09 |
Incyte Corporation |
Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
|
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
|
WO2022140647A1
(en)
*
|
2020-12-23 |
2022-06-30 |
Children's Hospital Medical Center |
Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
|
|
EP4049726A1
(en)
|
2021-02-25 |
2022-08-31 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Imidazo[1,2-a]pyrazines as inhibitors of haspin and therapeutic uses thereof
|
|
MX2023010941A
(es)
*
|
2021-03-17 |
2023-11-28 |
Janssen Sciences Ireland Unlimited Co |
Compuestos antibacterianos.
|